Top 50 Life Science VC Funds & Investors in Europe (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Sofinnova Partners
VC Fund
|
20 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.6M–$109M |
|
SOSV
VC Fund
|
20 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Parkwalk Advisors
VC Fund
|
17 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $1.1M–$46M |
|
Bpifrance
VC Fund
|
17 | France, United States, Switzerland | Seed, Series A | Software, Information Technology, Health Care | $726k–$34M |
|
Oxford Science Enterprises
VC Fund
|
14 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.3M–$168M |
|
UK Innovation & Science Seed Fund
VC Fund
|
14 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $458k–$14M |
|
Kurma Partners
VC Fund
|
11 | France, Switzerland, Spain | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $2.3M–$95M |
|
Development Bank of Wales
VC Fund
|
10 | United Kingdom, Australia, United States | Seed, Debt Financing | Software, Health Care, Biotechnology | $18k–$4.1M |
|
Novo Holdings
VC Fund
|
10 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9M–$135M |
|
Seventure Partners
VC Fund
|
9 | France, United States, Germany | Series A, Series B | Biotechnology, Health Care, Software | $3.1M–$65M |
|
IQ Capital
VC Fund
|
9 | United Kingdom, United States, Germany | Seed, Series A | Software, Artificial Intelligence, Machine Learning | $1.3M–$44M |
|
Meusinvest (Noshaq)
VC Fund
|
8 | Belgium, France, Germany | Series A, Seed | Biotechnology, Health Care, Medical | $137k–$16M |
|
Centre for the Development of Industrial Technology (CDTI)
VC Fund
|
8 | Spain, United States, France | Grant, Seed | Biotechnology, Health Care, Software | $157k–$16M |
|
Nina Capital
VC Fund
|
7 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Software | $573k–$21M |
|
Bullnet Capital
VC Fund
|
7 | Spain, United States, Mexico | Seed, Series A | Software, Information Technology, Manufacturing | $587k–$11M |
|
GM&C Life Sciences Fund
VC Fund
|
7 | United Kingdom, Italy, Germany | Seed, Series A | Health Care, Biotechnology, Medical | $65k–$4.1M |
|
24 Haymarket
VC Fund
|
7 | United Kingdom, United States | Seed, Series A | Health Care, Software, Information Technology | $714k–$16M |
|
APEX Ventures
VC Fund
|
7 | Germany, United Kingdom, Austria | Seed, Series A, Pre-Seed | Artificial Intelligence, Software, Health Care | $511k–$22M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
7 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $1.1M–$33M |
|
Selvedge Venture
VC Fund
|
7 | United Kingdom, Singapore | Seed, Pre-Seed, Series A | Health Care, Biotechnology, Life Science | $1.1M–$30M |
|
Amino Collective
VC Fund
|
7 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Artificial Intelligence | $125k–$37M |
|
Syncona Partners LLP
VC Fund
|
7 | United Kingdom, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.8M–$170M |
|
Capital Cell
VC Fund
|
7 | Spain, France, United States | Equity Crowdfunding, Seed | Health Care, Biotechnology, Medical | $137k–$1.9M |
|
Advent Life Sciences
VC Fund
|
7 | United States, United Kingdom, France | Series A, Series B | Biotechnology, Health Care, Medical | $5.5M–$105M |
|
Newable Private Investing
VC Fund
|
6 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | $196k–$5.2M |
|
Angels in MedCity
VC Fund
|
6 | United Kingdom, United States | Seed, Angel | Health Care, Biotechnology, Medical | $458k–$880k |
|
Idinvest Partners
VC Fund
|
6 | France, United States, Spain | Series B, Series A | Biotechnology, Software, Health Care | $3.3M–$66M |
|
Archangels
VC Fund
|
6 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | $1.3M–$8.3M |
|
Future Planet Capital
VC Fund
|
6 | United Kingdom, United States, Spain | Seed, Convertible Note | Biotechnology, Health Care, Software | $670k–$7.3M |
|
Techstart Ventures
VC Fund
|
6 | United Kingdom, Ireland, United States | Seed, Pre-Seed | Software, Information Technology, Health Care | $100k–$3.9M |
|
Kindred Capital
VC Fund
|
6 | United Kingdom, United States, Germany | Seed, Series A, Series B | Software, Biotechnology, Health Care | $1.5M–$73M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
6 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.8M–$50M |
|
Omnes Capital
VC Fund
|
6 | France, Germany, United States | Series A, Series B | Software, Biotechnology, Health Care | $3.5M–$53M |
|
Scottish Enterprise
VC Fund
|
6 | United Kingdom, United States, Switzerland | Grant, Seed | Biotechnology, Software, Health Care | $119k–$4.3M |
|
Voima Ventures
VC Fund
|
5 | Finland, Sweden, Norway | Seed, Pre-Seed, Series A | Biotechnology, Health Care, Artificial Intelligence | $439k–$30M |
|
Antler
VC Fund
|
5 | Singapore, Australia, United Kingdom | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $108k–$28M |
|
Maven Capital Partners
VC Fund
|
5 | United Kingdom, United States, Germany | Seed, Series A | Software, Information Technology, SaaS | $655k–$25M |
|
Enterprise Ireland
VC Fund
|
5 | Ireland, United States, United Kingdom | Seed, Series A | Software, Information Technology, Health Care | $494k–$12M |
|
Invivo Capital Partners
VC Fund
|
5 | Spain, France, Belgium | Seed, Series A | Biotechnology, Pharmaceutical, Health Care | $1.6M–$70M |
|
SR One
VC Fund
|
5 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$150M |
|
Ysios Capital
VC Fund
|
5 | Spain, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.2M–$135M |
|
Asabys Partners
VC Fund
|
5 | Spain, France, Belgium | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.2M–$135M |
|
PMV
VC Fund
|
5 | Belgium, United States, The Netherlands | Series A, Seed | Software, Biotechnology, Health Care | $549k–$40M |
|
CPT Capital
VC Fund
|
5 | United States, Israel, United Kingdom | Seed, Series A, Series B | Food and Beverage, Biotechnology, Food Processing | $1.3M–$226M |
|
R42 Group
VC Fund
|
5 | United Kingdom, United States, Austria | Seed, Pre-Seed, Series A | Biotechnology, Health Care, Software | $439k–$40M |
|
Google Ventures
VC Fund
|
5 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1.1M–$121M |
|
Epidarex Capital
VC Fund
|
5 | United Kingdom, United States, Germany | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $531k–$55M |
|
IFB Innovationsstarter
VC Fund
|
5 | Germany, United States | Seed, Grant | Software, SaaS, Artificial Intelligence | $80k–$3M |
|
Amadeus Capital Partners
VC Fund
|
5 | United Kingdom, United States, Spain | Seed, Series B, Series A | Software, Artificial Intelligence, Information Technology | $900k–$43M |
|
Inventure
VC Fund
|
5 | Finland, Sweden, United States | Seed, Series A, Series B | Software, Information Technology, Health Care | $549k–$25M |
| Access all 50 VC funds in Europe Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 317
- Round size: Series A $6.6M–$65M; Series B $10M–$109M; Series C $12M–$100M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
- Comet Biorefining — Comet Biorefining is a leading provider of sustainable high-quality cost-competitive cellulosic glucose technology for applications in renewable biofuels and biochemicals. The company’s proprietary technology allows for the conversion of wood, wheat straw, bagasse, corn stover and other agricultural waste materials into high purity cellulosicglucose syrup. These non-food sources offer lower cost and price stability when compared to food sugar sources such as corn or sugar cane. Demonstrated at 5 dry tons per day scale, Comet is focusing on commercial scale up and development of commercial partnerships with applications in renewables industries.
- Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 277
- Round size: Seed $1.1M–$5M; Series A $1.6M–$13M; Series B $2M–$46M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Paragraf — We Work to Develop Innovative and Useful End Products from Novel Materials. Our Analogue Sensors Are Designed to Provide Accurate Field Gradient Mapping & Alignment.
- Psyomics — Technology to support better mental health assessment - accelerating patients to the right care pathway, first time.
- PredictImmune — Pragmatic play menciptakan demo slot x500 yang merupakan slot online gratis. Nikmati slot demo pragmatic gacor gampang menang di demo pragmatic jamin gacor.
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 1268
- Round size: Seed $726k–$6.5M; Series A $2.7M–$34M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- AQEMIA — Aqemia is an in silico drug discovery start-up, whose ambition is to discover rapidly more innovative therapeutic molecules with better chances of success.
- Probabl — Open Source Commons for AI, Machine Learning, and Data Science.
- Ostrea — OSTREA is a pioneering company in the creation of high-performance materials based on bio-minerals: seashells.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 177
- Round size: Seed $1.3M–$12M; Series A $6.3M–$46M; Series B $13M–$168M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $327M in 2022
Portfolio highlights
- AlveoGene — Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy
- Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 135
- Round size: Seed $458k–$5.9M; Series A $2.9M–$14M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- MFX — MFX is a platform designed to accelerate the development and manufacturing of cell and gene therapies.
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- Hexigone Inhibitors — Hexigone aims to replace toxic chemicals used in the anti-corrosion market with our disruptive, novel, micro/nano reservoir technologies, creating 'smart' coatings. Our additives will enable the coatings to protect for longer in an intelligent manner, increasing the lifetime cycle of the end product, reducing the drain on primaryresources.
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, Spain
Investor stats
- Total investments: 138
- Round size: Seed $2.3M–$17M; Series A $3.8M–$95M; Series B $12M–$72M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- EvlaBio — EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical).
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- DAMAE Medical — Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis.
Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Debt Financing
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 237
- Round size: Seed $360k–$3.3M; Debt Financing $18k–$4.1M
- Lead/follow: 60% lead, 40% follow
- Last fund: May invest from a new fund soon — raised $25M in 2018
Portfolio highlights
- IQ Endoscopes — Fully Disposable Endoscopes for General Medical Use. A successful initial investment funding round completed, we are seeking future funding to take the IQ Scope to market.
- MeOmics Technology — MeOmics Technology is a biotech company with a focus on improving the diagnosis and treatment of mental health illnesses. The company operates in the manufacturing industry and has a team of 9 employees. The team includes experts in Neuronal Cell Biology and Neuropsychopharmacology. The company's mission is to leverage technology to enhancethe understanding and treatment of mental health conditions.
- Bond Digital Health — Bond Digital Health is a technology company developing end-to-end digital connectivity for the point-of-care diagnostics market. Developed by founders Ian Bond and Dave Taylor and originally designed as a patient self-management tool, Bond’s digital technology was remodeled to meet the needs of a client - a world-renowned innovator in point-of-carediagnostics and the lateral flow industry. The client required a digital platform consisting of a patient-facing mobile app and cloud data management for their new quantitative diagnostic test for chronic lung disease. They shared their experiences of working with us with a collaborator company who quickly commissioned Bond to develop a similar product for chronic wound care. Others in the lateral flow industry recognised that an affordable, compliant and scalable solution was available highlighting a huge unmet need in an expanding market. Bond is working in strategic partnerships with key industry leaders to create the next generation of digitally connected lateral flow diagnostics that provide an elevated user experience and enhanced real-time decision-making through the power of data aggregation and data analytics.Our regulatory strategy ensures that the solutions we create are secure, reliable and compliant with regulatory standards, making us a trusted partner to leaders in human health, animal health and agri-food globally.In Bond Digital Health we believe that collaborative working is the only way to tackle some of the major health challenges the world is nowadays facing. Our technology brings the life sciences industry closer together to create solutions that improve the lives of millions.Let’s make a difference together!
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 350
- Round size: Series A $9M–$125M; Series B $12M–$135M; Series C $30M–$118M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Verana Health — Verana Health is assembling the largest clinical databases in medicine to empower physicians and accelerate research for patients.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: France, United States, Germany
Investor stats
- Total investments: 238
- Round size: Series A $3.1M–$27M; Series B $3.4M–$65M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
- Pitchy — Create professional videos without technical expertise. Our online video editor helps you easily make business videos.
- Aenitis Technologies — We develop innovative devices for cells therapy processing using Acoustic Radiation Forces.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!IQ Capital is a Cambridge & London-based VC firm that invests in ‘deep tech’ companies capable of dominating their respective markets on a global scale. Initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through the Growth Fund. The team has achieved over 30 exits including toApple, Huawei, Google and Oracle.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 198
- Round size: Seed $1.3M–$13M; Series A $4.5M–$44M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Virti — Discover how our Immersive Learning Platform powers impactful & engaging learning experiences to transform enterprise workplace training.
- Nyobolt — Nyobolt develops high-power energy storage systems based on advanced lithium-ion battery technology designed for rapid charging and sustained high performance. The company focuses on battery systems that enable very fast energy replenishment, supporting applications where downtime needs to be minimized. Its technology combines specialized anodematerials, cell design, battery management systems, and power electronics to achieve high charge and discharge rates. The platform is used in sectors such as robotics, data centers, industrial equipment, and electric mobility where consistent high power delivery is required. It also develops integrated energy solutions that support demanding workloads like automated logistics systems and high-performance computing infrastructure. Nyobolt’s approach emphasizes optimizing cycle life, thermal stability, and energy density for repeated fast charging environments.
- Imperagen — Imperagen combines AI, QM/physics-based simulations, and high throughput lab testing to deliver true, verified enzyme improvements faster with lower cost.
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 77
- Round size: Seed $137k–$6M; Series A $3.3M–$16M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national andinternational levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Grant, Seed
- Geography: Spain, United States, France
Investor stats
- Total investments: 198
- Round size: Seed $562k–$5.9M; Grant $157k–$16M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Xoople — Xoople operates as an earth intelligence company. Xoople powers the next generation of Earth data intelligence to achieve a systematic understanding of physical changes on the Earth’s surface.
- Orga AI — Organ AI creates generative artificial intelligence that will help people. Its headquarters is located in Palma De Mallorca, Islas Baleares, Spain.
- Golden Owl —
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 88
- Round size: Seed $2M–$5.2M; Pre-Seed $573k–$2.4M; Series A $5M–$21M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Navidence — Navidence provides a transformative Real World Evidence (RWE) Design platform that enables organizations to efficiently adapt to the ever-increasing ecosystem of Real World Data (RWD) sources. The company unlocks the power of Computable Operational Definitions (CODefs) for RWE Design and RWD Assessment. Navidence's RWE Sherpa platform offerstools to streamline the process of defining an RWE study's data, making it easier for researchers to conduct their studies in the age of data.
- Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
- Sober Sidekick — Gamified peer to peer support
Independent Venture Capital Firm specialized in high technology Spanish start-ups. Helping tech entrepreneurs during the early stages of their company to build successful businesses
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Seed, Series A
- Geography: Spain, United States, Mexico
Investor stats
- Total investments: 64
- Round size: Seed $1M–$3.3M; Series A $587k–$11M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — raised $47M in 2023
Portfolio highlights
- FlexiiC — FlexiiC is a deep-tech firm developing printed, flexible integrated circuits for sustainable IoT and smart packaging solutions.
- Bioherent — Photonic biosensors for drug allergy diagnosis
- Impetux Optics — IMPETUX develops and markets patented technology to characterise the mechanical properties of living tissues and cells. We are focusing the application of our technology in fields like Mechanobiology where the study of diseases directly related with cell migration or development are demanding new techniques. We offer cutting-edge non-invasive to...
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Italy, Germany
Investor stats
- Total investments: 33
- Round size: Seed $65k–$936k; Series A $1.8M–$4.1M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- SurgaColl — SurgaColl Technologies is a medical device company developing novel tissue regeneration products for the surgical treatment of diseases of the bone, cartilage and other human tissue. Based on technology developed at the Tissue Engineering Research Group (TERG) of the Royal College of Surgeons in Ireland (RCSI), headed by Professor Fergal O’Brien,the company aims to become a leader in the field of regenerative medical devices.
- Acea Health — Acea Health is a digital healthcare company developing an application called Flynotes - a new digital consent platform. Flynotes analyses a number of factors, including the patient’s background, to deliver personalised risks and benefits. Flynotes aims to be the go-to solution for consent in healthcare. .
- Nexus Labs (Surgical Teaching) — Nexus Labs is an interactive learning resource for medical students.
24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growthagenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 104
- Round size: Seed $714k–$3.8M; Series A $1.6M–$16M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- DrDoctor — We envision a remote-first healthcare system which meets demand without sacrificing care quality, delivered via our Patient Engagement Platform
- DefiniGEN — Generate metabolic disease phenotypes in primary-like human cells using the best-in-class human iPSC differentiation platform. Find out more here!
- Kelda Technology — Kelda Technology is a British clean tech business that develops water-in-air shower products that halve water usage and water heating costs through patented shower technology. Kelda Technology has adapted cutting edge automotive and aerospace technology to produce a revolutionary “water-in-air” shower system that halves water use without any lossin performance. Water is broken into droplets to form a comfortable spray which is accelerated using a globally patented jet-type nozzle. Not only does it halve water costs, but also halves associated heating costs.The Kelda shower system holds appeal for a wide range of sectors, including gym and leisure, hotels and accommodation providers, healthcare, and maritime – all industries where water efficiency is key. The product has completed in-market validation and commercial trials, is in manufacture and the company has already signed installation deals with some of the largest leisure operators in the UK and Latin America.Kelda Technology was recently chosen as one of the top 30 cleantech companies in the world at the New Energy Start-Up awards 2016 and was this week shortlisted by the UK Business Angels Association for Best Investment in a Disruptive Tech Business.
APEX Ventures is a deep-tech and medical-focused venture capital firm.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, United Kingdom, Austria
Investor stats
- Total investments: 53
- Round size: Seed $1.3M–$8M; Pre-Seed $511k–$9.1M; Series A $2.2M–$22M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- GEMESYS — Gemesys creates a chip that functions similarly to the human brain in order to overcome processing constraints and empower AI with the hardware it needs to complete its destiny
- HyperHeat — HyperHeat is building a cutting-edge, all-electric heating solution designed to reach temperatures of up to 2,000°C. Using renewable electricity HyperHeat is providing an efficient alternative to fossil fuel combustion. With an efficiency rate of up to 98%, HyperHeat is ideal for retrofitting industrial processes, enabling significant CO2reductions across industries like steel, cement, and chemicals. The scalable technology offers a cost-efficient approach to decarbonizing thermal processes, with a potential to reduce global CO2 emissions by over 4.5 gigatons annually.
- TriLite Technologies — The world's smallest projection displays from TriLite take laser beam scanning technology to the next level, for augmented vision as light as the eyewear of today.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 583
- Round size: Seed $1.1M–$7.3M; Series A $3.5M–$33M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- DcubeD — Accelerate your space exploration through durable and affordable Release Actuators, Solar Arrays, and Deployables from DCUBED.
- FINE Legal — fine. holt Dir Dein Geld einfach, digital und ohne Risiko.
- NAVAN Technologies — NAVAN Technologies, Inc., (NAVAN) is a pre-clinical stage biotechnology company developing and commercializing its proprietary NanoStraw platform technology, which establishes a direct, physical connection into cells to overcome a huge challenge faced by researchers globally: delivering material into hard-to-transfect-cells in an efficient yetgentle and non-perturbative manne
Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Life Science
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, Singapore
Investor stats
- Total investments: 14
- Round size: Seed $1.4M–$9.6M; Pre-Seed $1.1M–$2.5M; Series A $3.5M–$30M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
- Mesh Bio — We enable digital transformation of care delivery through clinical workflow automation and predictive analytics, built on gold standard clinical guidelines and best practices.
- Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 45
- Round size: Seed $2.4M–$15M; Pre-Seed $125k–$7.8M; Series A $12M–$37M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Calibre — Calibre uses causal AI in conjunction with clinical expertise to help people understand what is truly influencing their health and how to modify it.
- Modern Relay — Modern Relay provides context graph for enterprise AI.
- Theorema — Autonomous R&D agents for biotech, pharma, chemicals, and materials. Theorema analyzes data, recovers R&D costs, and accelerates discovery. #1 on BixBench.
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 62
- Round size: Seed $1.8M–$17M; Series A $17M–$110M; Series B $24M–$170M
- Lead/follow: 58% lead, 42% follow
Portfolio highlights
- Apini Therapeutics — Apini is a creating novel small chemical two most prevalent types of inflammatory bowel disease.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Re-Aim Therapeutics — Re‑Aim Therapeutics is a UK‑based biotech start‑up developing functional cures for T cell–mediated autoimmune diseases by selectively depleting pathogenic T‑cell subsets. Its lead asset, REA‑001, is a monoclonal antibody designed to potently and precisely eliminate disease‑causing type‑17 T cells, aiming to reset the immune system and achievedurable, treatment‑free remission in multiple autoimmune conditions.
Capital Cell is a crowdinvesting platform for biotech and life sciences companies. Mixing VC, business angels, accredited investors, and the power of the crowd, the company is building a global meeting point for companies and researchers working, fostering, and financing tomorrow’s medical science.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Equity Crowdfunding, Seed
- Geography: Spain, France, United States
Investor stats
- Total investments: 51
- Round size: Seed $384k–$1.9M; Equity Crowdfunding $137k–$1.3M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- DYNAMICS VR — Dynamics VR provides rehab software for clinics to tackle musculoskeletal pain and movement impairments caused by brain trauma.
- Axoltis Pharma — Axoltis Pharma is a biotech company that develops drugs for degenerative and traumatic neurological disorders.
- EVis Bioscience — EVis Bioscience offers gene delivery solutions using extracellular vesicles, lipid nanoparticles, and hybrid systems.
Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 70
- Round size: Series A $5.5M–$51M; Series B $21M–$105M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- Cyted — Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use AI and novel biomarkers to improve patient outcomes.
- Glycomine — We are developing a PMM2-CDG substrate replacement therapy. GLM101 is a mannose-1 phosphate treatment.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 103
- Round size: Seed $196k–$3.9M; Series A $1.3M–$5.2M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
- NuVision — NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.
- RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.
Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies.With aparticular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas.Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Angel
- Geography: United Kingdom, United States
Investor stats
- Total investments: 18
- Round size: Seed $458k–$880k
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
- Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
- DynamX Medical — DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series B, Series A
- Geography: France, United States, Spain
Investor stats
- Total investments: 252
- Round size: Series A $3.3M–$24M; Series B $7.8M–$66M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $88M in 2021
Portfolio highlights
- LumApps — LumApps is the only intranet packaged solution that enables employees to feel connected to their organization and engaged in their work from anywhere by delivering a modern, smart digital headquarters that empowers your employees to design a work experience that works for them.
- Ornikar — Ornikar is an online driving school that offers radically cheaper, uncomplicated and faster offer to obtain a driving license.Ornikar relies on a network of state-qualified teachers to offer an apprenticeship in mobile driving at reduced prices. The cmpany is an an online driving school more in tune with the demand of current and futuregenerations.The company's mission is to make the driver's license exam cheaper and its learning more enjoyable.
- Pretty Simple — Video games studio based in Paris, France. Makers of Criminal Case and Sorcery School.
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 85
- Round size: Seed $1.3M–$3.9M; Series A $1.6M–$8.3M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- BioCaptiva — BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
- Bioliberty — Engineering the future of physical and occupational therapy.
- Earth Blox — Earth Blox is a paradigm shift for teaching Earth observation skills to everyone from children to university students & professionals.
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 168
- Round size: Seed $670k–$7.3M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely still investing — raised $23M in 2022
Portfolio highlights
- Nourished — At Nourished we create innovative. personalised nutrition stacks that are truly unique to you. Vegan, waste-free and always made to order.
- NeoVac — NeoVac is creating revolutionary, unique and proprietary next-generation lipid nanoparticles to enable better RNA vaccines and treatments for various diseases.
- K3 Metrology — K3 Metrology is a specialist metrology company commercialising laser‑based 3D coordinate measurement technology developed at the National Physical Laboratory. The company’s platform is designed to provide high‑accuracy, uncertainty‑aware dimensional data in large‑volume industrial environments, supporting inspection and assembly processes inadvanced manufacturing. Its systems integrate into production workflows where traceable measurements are required across complex geometries and large structures. The technology is applied in sectors such as aerospace, defence, and nuclear, where dimensional integrity and process control are critical.
Techstart Ventures is a first-cheque investor for extraordinary founders pursuing uncapped global opportunities.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, Ireland, United States
Investor stats
- Total investments: 162
- Round size: Seed $249k–$3.9M; Pre-Seed $100k–$1.6M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- Gigged.AI — Fill skill gaps using our on-demand talent network. Get AI-powered, real-time visibility over your employee and agent capabilities to power internal mobility.
- Product Guru — Although there has been a significant change of pace in the technology used within the retail sector, the process of finding the products that drive the market has really remained at a stand-still. With more and more small, specialist suppliers driving innovation in the sector, it has been harder than ever for buyers to be able to consider alloptions.
- Cloudsmith — Cloudsmith is the only universal, cloud-native solution for software artifact management and software supply chain security. Start your free trial today.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!A new model for Venture Capital where every founder we back becomes a co-owner of the fund
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 112
- Round size: Seed $1.5M–$16M; Series A $7.9M–$35M; Series B $13M–$73M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Paddle — The revenue engine powering payments for n8n, Letterboxd & AdGuard. One platform that handles subscription billing, payments and compliance.
- how.fm — Training software for better onboarding processes and digital store floor management. Train staff with no effort and language barriers.
- Scarlet — Continuous compliance
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 100
- Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
- ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B
- Geography: France, Germany, United States
Investor stats
- Total investments: 181
- Round size: Series A $3.5M–$44M; Series B $4.4M–$53M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $403M in 2020
Portfolio highlights
- VSORA — VSORA provides high performance companion solutions combining AI and signal processing to enable autonomous driving and ADAS
- SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Grant, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 360
- Round size: Seed $375k–$3.9M; Grant $119k–$4.3M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Pneumagen — Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology.
- Trojan Energy — Trojan Energy support the roll-out of its on-street flat and flush electric vehicle charging points, which aims to solve the issue for vehicle owners who do not have access to off-street parking.
- Smart Green Shipping — smart green shipping alliance. economically, socially and environmentally superior shipping solutions.
Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: Finland, Sweden, Norway
Investor stats
- Total investments: 59
- Round size: Seed $1M–$5.9M; Pre-Seed $439k–$2.1M; Series A $3.9M–$30M
- Lead/follow: 64% lead, 36% follow
Portfolio highlights
- Nucu — The Nucu Pad is a multisensory baby pad that soothes your baby to sleep with womb-like feelscapes.
- Adamant Health — Adamant Health’s unique technology to analyse Parkinson’s disease symptoms is based on over 15 years of academic research at the University of Eastern Finland. With the technology, clinicians have several days detailed visibility to the patient’s symptoms and is able to optimise the treatment accordingly. Pharma companies benefit from the objectiveand long-term RW data in their clinical and post market studies and can utilise it as complementary diagnostics tool for personalised medication.
- Sofi Filtration — Innovation in Industrial Liquid Filtration
Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Singapore, Australia, United Kingdom
Investor stats
- Total investments: 1818
- Round size: Seed $186k–$4.6M; Pre-Seed $108k–$750k; Series A $4.6M–$28M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely actively investing — fresh fund, raised $72M in 2024
Portfolio highlights
- Sapyen — We take the fear out of infertility for men. Test for it at home, without stepping out to the hospital and get personalised health recommendations to improve sperm health and increase your chances of conceiving.
- Visoid — Render your 3D models with ease! Quick and easy rendering software for architects, powered by AI. Try Visoid for free!
- One Key Access — One Key Access is an interface to the world of couriers to enable 24/7 frictionless deliveries.
Maven is one of the UK's leading private equity and investment firms. We provide essential capital and expertise to help businesses unlock their potential.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 202
- Round size: Seed $655k–$5.3M; Series A $2.2M–$25M
- Lead/follow: 73% lead, 27% follow
Portfolio highlights
- Bright — Bright Network has a range of graduate careers available. Whatever the sector you want to go into Bright Network will help you find your dream job.
- ProofID — We are identity experts. We manage all aspects of your IAM program, from design and deployment, through to optimisation and ongoing support.
- Guru Systems — Intelligent technology for the future of heat. Guru Systems provides market-leading hardware and data analytics platforms for heat networks, gas boilers and heat pumps. Our technology improves the performance of these systems for residential developers, heat suppliers, customers and our planet.
Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 506
- Round size: Seed $494k–$3.3M; Series A $2.2M–$12M
- Lead/follow: 19% lead, 81% follow
- Last fund: May invest from a new fund soon — raised $1.1M in 2021
Portfolio highlights
- Tirlan — Tirlan is an agricultural company that supplies agri-food and farm input materials to the framing sector.
- Pulsate — Pulsate enables direct communication with customers based on their location, context, interests and behaviours. Pulsate allows you to design and push rich media content directly to customers devices. Deepen the relationship by establishing a customer dialogue. Allow users to reply to your campaigns, provide feedback and keep complaints outside ofsocial media. Maximize foot traffic by targeting street level or competitor locations. Combine with segmentation for optimal results. iBeacons:tm: enable you to understand indoor customer location and context with incredible accuracy. Easily manage deployment and configuration of iBeacons:tm: with the Pulsate cloud platform. Gain a deeper understanding of your mobile customers and a comprehensive view of each mobile campaign.
- Lakeland Dairies — Lakeland Dairies, a major dairy processing co-operative, operates within a fifteen county catchment area across the northern half of the island of Ireland. The Group processes about one billion litres of quality milk annually into a range of value added dairy foodservice products and functional dairy food ingredients.
Invivo Capital is a team of knowledgeable professionals with the scientific, technical, and financial know-how required to analyze and make investments that provide value to the invested company. They also have a network of contacts and key strategic relationships in the health ecosystem.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Seed, Series A
- Geography: Spain, France, Belgium
Investor stats
- Total investments: 26
- Round size: Seed $1.6M–$13M; Series A $2.2M–$70M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $44M in 2019
Portfolio highlights
- ARTHEx Biotech — ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases.
- Gyala Therapeutics — Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies. CAR-T (chimeric antigen receptor T cells) is a type of gene therapy in which T lymphocytes -a type of white blood cells that play a key role in immune responses- are extracted from the patient and modified to attack tumour cells. T lymphocytesare obtained through apheresis (a technique that allows separation of blood components) and genetically reprogrammed with a receptor that binds to a tumor factor. When these cells are transduced back to the patient, they are to specifically recognize tumour cells and attack them. Several types of CAR-T cells have demonstrated efficacy in the treatment of leukemias and B cell lymphomas.
- Telomere Therapeutics — Telomere Therapeutics is a University of Barcelona spinoff developing telomerase gene therapy to treat pulmonary fibrosis
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 189
- Round size: Series A $3.7M–$140M; Series B $15M–$114M; Series C $22M–$150M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- River Vision Development — River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Spain, United States, Switzerland
Investor stats
- Total investments: 79
- Round size: Series A $2.2M–$63M; Series B $17M–$135M; Series C $27M–$80M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Cytoki Pharma — Cytoki Pharma is a biotechnology company developing a portfolio of IL-22-based drugs as a new treatment paradigm for serious diseases involving epithelial injury.
Asabys Partners is a venture capital firm that invests across the board in human healthcare. The company is active in the health-tech and biopharma industries and aims to invest in Spain and abroad in innovative and transformative technologies. Asabys Partners are motivated by the idea of pushing the boundaries of science and medicine. This is donethrough the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: Spain, France, Belgium
Investor stats
- Total investments: 38
- Round size: Seed $1.2M–$13M; Series A $7M–$55M; Series B $18M–$135M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely still investing — raised $117M in 2022
Portfolio highlights
- Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
Do and dare company
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Seed
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 152
- Round size: Seed $549k–$4.3M; Series A $2.7M–$40M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Animab — Animal Health Company
- Sentea — Sentea makes fibre optic Sensing affordable to the industry and enables continuous monitoring even in harsh environments.
- CHILI publish — Allow users to edit customizable documents, or fully automate artwork generation. Output files are ready to use for print and digital.
Investing in the Future of Protein.We invest in visionary founders creating the future of food and materials.
Show more...Investment focus
- Industry: Food and Beverage, Biotechnology, Food Processing
- Stage:Seed, Series A, Series B
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 59
- Round size: Seed $1.3M–$7.5M; Series A $6M–$46M; Series B $15M–$226M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Shiru — Discover Shiru. We are an Ingredient Company that Identifies and Creates Functional Ingredients for the Plant-Based Industry.
- Xias Bio — Xias Bio is a biotechnology startup specializing in the production of recombinant proteins, offering formulators advanced soluble, active ingredients with improved attributes such as enhanced gel and film formation, as well as antioxidant properties. The company creates non-immunogenic natural motifs to produce a better delivery platform offunctionalities for research, beauty, and healthcare.
- Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Austria
Investor stats
- Total investments: 34
- Round size: Seed $654k–$8M; Pre-Seed $439k–$2M; Series A $4.2M–$40M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
- Stamp Free — stampfree.ai Digital Shipping Solutions enables customers to send parcels and returns with just a phone conveniently and securely.
- Cordance Medical — Improving outcomes for patients with brain diseases
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1110
- Round size: Seed $1.1M–$16M; Series A $6M–$100M; Series B $15M–$121M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- Cord Project — Cord is incredibly simple, incredibly fast voice messaging that lets you chat with one friend or shout to a whole group of friends. Start chatting for free on iPhone or Android now.
- Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
- Cambridge Epigenetix — CEGX develops products for academia and industry, democratizing step-changes in accuracy and cost.
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 48
- Round size: Seed $531k–$8.5M; Series A $2.6M–$38M; Series B $2.4M–$55M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Leucid Bio — CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
- Epsilogen — IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.
Show more...Investment focus
- Industry: Software, SaaS, Artificial Intelligence
- Stage:Seed, Grant
- Geography: Germany, United States
Investor stats
- Total investments: 87
- Round size: Seed $365k–$3M; Grant $80k–$165k
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- mo:re GmbH — We offer standardized tissue cultures and protocols to better predict drug responses and investigate disease models.
- Atrya — Atrya develops regulatory-compliant blockchain payments for international companies.
- DEALCIRCLE — DealCircle is a digital M&A solution and partner of hundreds of M&A advisors. We support in identifying buyers and addressing the market. This provides investors access to a comprehensive deal flow of relevant projects.
Amadeus Capital Partners, Venture Capital For Technology Companies. We Back Entreprenuers To Win. Contact Our Experienced Team Of Investors Today
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series B, Series A
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 237
- Round size: Seed $900k–$9.2M; Series A $2.6M–$30M; Series B $6.8M–$43M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $88M in 2023
Portfolio highlights
- Tenzo — Tenzo is a restaurant analytics and AI forecasting platform for restaurants, pubs and cafes. Tenzo makes running restaurants easy with full data visibility.
- Slamcore — Positioning, mapping and perception | State-of-the-art visual SLAM turns sensor data into actionable, spatial understanding for your vehicles.
- Unifyr — IDC MarketScape Leader 2025. AI-native PRM platform for partner onboarding, enablement, deal registration, and through-channel marketing.
Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A, Series B
- Geography: Finland, Sweden, United States
Investor stats
- Total investments: 172
- Round size: Seed $549k–$5.9M; Series A $1.3M–$17M; Series B $1.3M–$25M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $169M in 2022
Portfolio highlights
- Omocom — Omocom offers safe, simple and secure insurance for all kind of renting, sharing and re-using, digitally, automated and integrated into the sales flow of the platform
- AnotherblockAnotherblock AB — Anotherblock is Transforming Music into an Investable Asset Class. We Specialize in Music Investments, Music Rights, Catalog Valuations, and Royalty Management.
- Valuebeat — Grow your culture. Backed by data. Platypus is the HR and recruitment tool that measures cultural drivers of people across the organization to help you qualify decisions on hiring and managing your culture.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science VC Funds in Europe investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 VC funds investing in Europe Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!